Table 1 Characteristics of the study population. Data presented as mean and 95% CI.Differences between groups are analyzed using one-way ANOVA or Pearson chi-square test. Results are given as mean and 95% Confidence Interval. a, b, c, d are analyzed using t-test; a: p > 0.05 vs. HIV + T2D-, b: p < 0.05 vs. HIV + T2D-, c: p > 0.05 vs. HIV-T2D+, d: p < 0.05 vs. HIV-T2D+. BMI: Body Mass Index
N | HIV + T2D+ | HIV + T2D- | HIV-T2D+ | HIV-T2D- | P |
|---|---|---|---|---|---|
25 | 25 | 22 | 28 | ||
Age (years) | 58 (55–61) | 55 (50–58) | 57 (53–60) | 57 (55–60) | 0.638 |
Gender (% male) | 92 | 96 | 89 | 72 | 0.079 |
CD4 count (cells/μL) | 672 (554–790)a | 663 (520–807) | 1254 (980–1528) | 849 (720–978) | <0.001 |
CD8 count (cells/μL) | 994 (675–1312)a | 884 (645–1124) | 567 (428–706) | 458 (372–544) | 0.001 |
Nadir CD4 (cells/μL) | 180 (121–240) | 266 (171–360) | − | − | 0.392 |
HIV RNA (copies/mL) | 26 (16–38) | 27 (15–40) | − | − | 0.757 |
Time since HIV diagnosis (months) | 200 (153–248) | 172 (112–232) | − | − | 0.740 |
Treatment duration (months) | 143 (116–170) | 124 (89–159) | − | − | 0.394 |
Fasting BG (mmol/L) | 8.0 (6.9-9.0)b,c | 5.3 (5.0-5.4) | 9.0 (7.9-10.3) | 5.3 (5.1-5.6) | <0.001 |
HbA1c (mmol/mol) | 48 (44–52)b,d | 35 (33–37) | 60 (54–65) | 36 (32–39) | <0.001 |
BMI | 26 (24–28)a,d | 25 (23–27) | 28 (27–30) | 25 (24–26) | 0.007 |
Smoking (%) | 44 | 24 | 23 | 21 | 0.233 |
Systolic BP (mmHg) | 132 (125–139) | 127 (121–133) | 138 (131–144) | 135 (130–140) | 0.115 |
Diastolic BP (mmHg) | 82 (77–87) | 80 (77–84) | 86 (82–91) | 82 (79–85) | 0.317 |
CVD10 (Framingham Risk Score) | 29 (22–35)c | 14 (10–18) | 25 (19–30) | 16 (12–20)a | <0.001 |